Naflox (Norfloxacin)

Norfloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes that control DNA supercoiling and separation during replication. By binding to these enzymes, the drug halts DNA synthesis, leading to bacterial cell death. This bactericidal action provides rapid eradication of susceptible ocular pathogens.

The dosing regimen for Naflox is determined by the prescribing clinician based on the type and severity of the ocular infection, patient age, and response to therapy. The product is supplied as an ophthalmic solution, and the prescriber specifies the number of drops, frequency, and duration of treatment.

Safety data for norfloxacin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Naflox, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Naflox (norfloxacin) belongs to the fluoroquinolone class and offers broad‑spectrum activity against many Gram‑negative and Gram‑positive ocular pathogens. Compared with older agents such as chloramphenicol, norfloxacin generally provides faster bacterial eradication and a lower risk of resistance, though choice of therapy should consider local susceptibility patterns and patient tolerance.

Store Naflox at room temperature, preferably below 25 °C, in its original container. Protect the bottle from direct light and moisture, and keep the cap tightly closed when not in use. Do not freeze the solution, and discard any product that appears discolored or contains particles.

Naflox is applied as an ophthalmic solution. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s), usually several times a day as directed by the prescriber. Patients should avoid touching the tip of the bottle to the eye or any surface to maintain sterility.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, corneal ulceration, and potential vision loss. Any sudden worsening of eye symptoms, widespread rash, or systemic allergic signs should prompt immediate medical evaluation.

Naflox should not be used by individuals with a known hypersensitivity to norfloxacin, other fluoroquinolones, or any component of the formulation. It is also contraindicated in patients with a history of severe ocular surface disease where the drug may exacerbate the condition, and it should be avoided in pregnancy or lactation unless clearly justified.